Mereo BioPharma Group plc
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
MREO$0.30+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated statements of cash flows
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(41,878) | $(43,253) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation | 7,598 | 7,390 |
| Depreciation | 157 | 143 |
| Amortization of intangible assets | 465 | 438 |
| Amortization of operating lease right-of-use assets | 527 | 507 |
| Change in fair value of warrants | (805) | 419 |
| Non-cash interest income | (104) | — |
| Non-cash interest expense | 228 | 1,351 |
| Foreign currency transaction loss/(gain) | 6,344 | (1,210) |
| Other income | (300) | — |
| Non-cash consideration, milestone payment | — | 1,750 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (84) | 2,980 |
| Research and development incentives receivable | 1,396 | (1,649) |
| Accounts payable | (1,378) | 146 |
| Accrued expenses and other liabilities | (2,394) | (1,192) |
| Operating lease liabilities | (743) | (654) |
| Net cash used in operating activities | (30,971) | (32,834) |
| Cash flows from investing activities | ||
| Payments for intangible assets | (300) | (699) |
| Purchase of property and equipment | (20) | — |
| Proceeds from out-licensing | 300 | — |
| Net cash used in investing activities | (20) | (699) |
| Cash flows from financing activities | ||
| Proceeds from exercise of warrants | 487 | — |
| Proceeds from issuance of ordinary shares | 39 | 47,000 |
| Transaction costs on issuance of ordinary shares | (199) | (853) |
| Net cash provided by financing activities | 327 | 46,147 |
| (Decrease)/increase in cash and cash equivalents | (30,664) | 12,614 |
| Cash and cash equivalents at January 1, | 69,802 | 57,421 |
| Effect of exchange rate changes | 1,854 | (233) |
| Cash and cash equivalents at December 31, | $40,992 | $69,802 |
| Supplemental disclosure | ||
| Cash paid for interest | 29 | 21 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.